title: Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study.
abstract: A total of 62 patients at high risk for recurrence of superficial bladder cancer were selected for a study designed to compare the prophylactic efficacy of different doses and schedules of sequential intravesical instillations of epirubicin and interferon-alpha-2b and to evaluate which sequence could enhance the release of cytokines in the urine. Our investigations showed a significant increase in urinary concentrations of interleukins in patients who received the sequential intravesical administration of epirubicin and interferon-alpha-2b. Higher urinary concentrations of interleukins and a lower recurrence rate were detected in patients who received interferon-alpha-2b 24h after epirubicin instillation.
authors.affiliation: Department of Urology, Civic Hospital, Palermo, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Serretta
authors.forename: G
authors.initials: G
authors.lastname: Corselli
authors.forename: B
authors.initials: B
authors.lastname: Piazza
authors.forename: D
authors.initials: D
authors.lastname: Lio
authors.forename: F
authors.initials: F
authors.lastname: Gervasi
authors.forename: S
authors.initials: S
authors.lastname: Salerno
authors.forename: M
authors.initials: M
authors.lastname: Pavone-Macaluso
mesh_terms: D000283:Administration, Intravesical; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D007375:Interleukin-1 / Q000652:urine; D007376:Interleukin-2 / Q000652:urine; D015847:Interleukin-4 / Q000652:urine; D007378:Interleukins / Q000652:urine*; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007375:Interleukin-1; D007376:Interleukin-2; D007378:Interleukins; D011994:Recombinant Proteins; D015847:Interleukin-4; D015251:Epirubicin